Company / Return on Equity (ROE)
RxSight, Inc. Return on Equity (ROE) History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-17.6%
FY2025
5-year range
-54.2% / 20.0%
FY2021-FY2025
Trend
+25.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
RxSight, Inc. reports negative total equity of -17.6% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-17.6% in FY2025 with a 3-year CAGR of +36.5%.
Improved from -41.6% to -17.6% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +36.5pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- RxSight, Inc.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 25.7% year-over-year.
- Peak return on equity (roe) was recorded in FY2021.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.59 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -17.6% | +25.7% |
| FY2024 | -23.7% | +43.0% |
| FY2023 | -41.6% | +23.1% |
| FY2022 | -54.2% | -371.5% |
| FY2021 | 20.0% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026